1. A 64-year-old man with type 2 diabetes mellitus (T2DM) and a history of myocardial infarction two years ago is on metformin with an HbA1c of 7.8%. His cardiologist asks which add-on agent class has the strongest trial evidence for reducing the dominant atherosclerotic endpoint of non-fatal myocardial infarction (MI), non-fatal stroke, and cardiovascular death in patients with established atherosclerotic cardiovascular disease (ASCVD). Which class should be selected?
A) Glucagon-like peptide-1 receptor (GLP-1R) agonists, which demonstrated reductions in major adverse cardiovascular events including non-fatal MI and stroke in trials such as LEADER and SUSTAIN-6
B) Dipeptidyl peptidase-4 (DPP-4) inhibitors, which reduce atherosclerotic events through incretin-mediated plaque stabilization
C) Sulfonylureas, which reduce atherosclerotic events by improving glycemic control through enhanced insulin secretion
D) Thiazolidinediones (TZDs), which reduce atherosclerotic endpoints through peroxisome proliferator-activated receptor-gamma (PPAR-gamma) mediated anti-inflammatory effects
E) Alpha-glucosidase inhibitors, which reduce postprandial glucose excursions and thereby lower atherosclerotic risk
ANSWER: A
Rationale:
For the dominant atherosclerotic endpoint of non-fatal MI, non-fatal stroke, and cardiovascular death, GLP-1R agonists have the strongest cardiovascular outcome trial evidence. Liraglutide (LEADER trial) and subcutaneous semaglutide demonstrated significant reductions in major adverse cardiovascular events (MACE), with a mechanism consistent with anti-atherosclerotic effects on plaque stability, endothelial function, and inflammation.
Option B: Option B is incorrect because DPP-4 inhibitors have demonstrated neutral cardiovascular outcomes in their CVOTs and do not reduce atherosclerotic MACE.
Option C: Option C is incorrect because sulfonylureas have no proven atherosclerotic event reduction and carry hypoglycemia risk.
Option D: Option D is incorrect because TZDs are not used for atherosclerotic MACE reduction and carry heart failure risk through fluid retention.
Option E: Option E is incorrect because alpha-glucosidase inhibitors have no established atherosclerotic outcome benefit in this population.
2. In a patient with T2DM and established ASCVD, sodium-glucose cotransporter 2 (SGLT-2) inhibitors provide a benefit that is complementary to, rather than identical to, that of GLP-1R agonists. Which statement best characterizes the dominant cardiovascular benefit signal of SGLT-2 inhibitors in this population?
A) They produce the largest reduction in non-fatal stroke seen across the diabetes cardiovascular outcome trial program
B) They reduce atherosclerotic plaque burden directly through anti-inflammatory effects on the arterial wall
C) They reduce cardiovascular death and heart failure hospitalization through volume unloading and natriuresis, with little effect on non-fatal MI or stroke
D) They reduce non-fatal MI primarily through coronary plaque regression demonstrated on serial angiography
E) They lower atherosclerotic events exclusively through their glucose-lowering and weight-reducing effects
ANSWER: C
Rationale:
SGLT-2 inhibitors in the established ASCVD context provide reduction in cardiovascular death and heart failure hospitalization rather than reduction in non-fatal MI or stroke. EMPA-REG OUTCOME demonstrated a 38% reduction in cardiovascular death and a 35% reduction in heart failure hospitalization, with no significant effect on non-fatal MI or stroke; this hemodynamic benefit operates through volume unloading and natriuresis.
Option A: Option A is incorrect because the largest non-fatal stroke reduction was seen with semaglutide, a GLP-1R agonist, not with SGLT-2 inhibitors.
Option B: Option B is incorrect because direct anti-atherosclerotic plaque effects are attributed to GLP-1R agonists, not to the hemodynamic mechanism of SGLT-2 inhibitors.
Option D: Option D is incorrect because SGLT-2 inhibitors did not significantly reduce non-fatal MI and the claim of angiographic plaque regression is fabricated.
Option E: Option E is incorrect because the cardiovascular benefit of SGLT-2 inhibitors is independent of glycemic control and is observed even in patients without diabetes.
3. The ADA 2024 Standards of Care reserve GLP-1R agonists and SGLT-2 inhibitors with proven ASCVD benefit for patients with established ASCVD or very high risk, not merely for all patients with multiple risk factors. Which patient meets the definition of established ASCVD as used in the cardiovascular outcome trials?
A) A 55-year-old with hypertension, dyslipidemia, and a family history of coronary disease but no prior cardiovascular event
B) A 60-year-old with a prior ischemic stroke and a history of coronary revascularization
C) A 58-year-old with an elevated coronary artery calcium score but no symptoms and no prior event
D) A 62-year-old with metabolic syndrome and an HbA1c of 9% but no documented vascular disease
E) A 50-year-old with isolated microalbuminuria and no macrovascular history
ANSWER: B
Rationale:
Established ASCVD for cardiovascular outcome trial purposes is defined as a history of myocardial infarction, unstable angina requiring hospitalization, coronary revascularization, ischemic stroke or transient ischemic attack, or hemodynamically significant peripheral arterial disease. A patient with prior ischemic stroke and coronary revascularization clearly meets this definition.
Option A: Option A is incorrect because multiple risk factors without a prior event place the patient in the high-risk but not established-ASCVD category, where atherosclerotic event-reduction evidence is substantially weaker.
Option C: Option C is incorrect because an elevated calcium score without a clinical event does not constitute established ASCVD by trial criteria.
Option D: Option D is incorrect because metabolic syndrome and poor glycemic control without documented vascular disease do not meet the definition.
Option E: Option E is incorrect because microalbuminuria reflects kidney involvement and is not a macrovascular ASCVD event.
4. When sequencing pharmacotherapy in T2DM with established ASCVD, clinicians generally begin with a glycemic backbone agent before adding agents selected for cardiovascular benefit. Which statement correctly describes this backbone agent and its renal threshold?
A) Glipizide is the preferred backbone and may be continued at any level of renal function
B) Pioglitazone is the preferred backbone because it provides cardiovascular protection through PPAR-gamma activation
C) Insulin is the required first agent in all patients with established ASCVD regardless of HbA1c
D) Metformin is the typical glycemic backbone if tolerated and renal function permits, with a continuation threshold of estimated glomerular filtration rate (eGFR) at or above 30 mL per minute per 1.73 m squared
E) A GLP-1R agonist should always be the first agent, with metformin reserved for later intensification
ANSWER: D
Rationale:
Practical drug sequencing in T2DM with established ASCVD typically begins with metformin as the glycemic backbone if tolerated and renal function permits (eGFR at or above 30 mL per minute per 1.73 m squared), followed by a GLP-1R agonist for ASCVD risk reduction and an SGLT-2 inhibitor as the third agent.
Option A: Option A is incorrect because glipizide is not a cardiovascular-preferred backbone and sulfonylureas carry hypoglycemia risk that increases as renal function declines.
Option B: Option B is incorrect because pioglitazone is not the glycemic backbone and carries heart failure risk through fluid retention.
Option C: Option C is incorrect because insulin is not the required first agent in ASCVD; it is reserved for specific indications rather than universal first-line use.
Option E: Option E is incorrect because metformin, not a GLP-1R agonist, is the conventional first-line backbone, with the GLP-1R agonist added for cardiovascular benefit.
5. A patient with T2DM has both established ASCVD and clinical heart failure. The ADA explicitly recommends combining a GLP-1R agonist with an SGLT-2 inhibitor in this scenario. What is the pharmacological rationale for using both classes together?
A) The two classes share an identical mechanism, so combining them simply doubles the magnitude of a single effect
B) SGLT-2 inhibitors potentiate the glucose-lowering effect of GLP-1R agonists, which is the primary reason for combining them
C) GLP-1R agonists are added solely to counteract the genitourinary infection risk of SGLT-2 inhibitors
D) The combination is recommended only to reduce pill burden and improve adherence
E) GLP-1R agonists provide anti-atherosclerotic protection against non-fatal MI and stroke, while SGLT-2 inhibitors provide complementary hemodynamic protection against cardiovascular death and heart failure hospitalization, giving dual-pathway coverage
ANSWER: E
Rationale:
The hemodynamic benefit of SGLT-2 inhibitors, operating through volume unloading and natriuresis, is complementary to the anti-atherosclerotic benefit of GLP-1R agonists, which act on plaque stability, endothelial function, and inflammation. Combining both classes therefore provides dual-pathway protection, covering both atherosclerotic events and heart failure or cardiovascular death, which is why the ADA explicitly recommends the combination when ASCVD and heart failure coexist.
Option A: Option A is incorrect because the two classes act through distinct mechanisms rather than an identical one.
Option B: Option B is incorrect because the rationale for combining them is complementary cardiovascular protection, not glycemic potentiation.
Option C: Option C is incorrect because GLP-1R agonists are not added to offset SGLT-2 inhibitor infection risk.
Option D: Option D is incorrect because the combination is driven by complementary outcome benefits, not by pill-burden considerations.
6. A patient with T2DM and chronic kidney disease (CKD) has a falling estimated glomerular filtration rate (eGFR). The clinical team is reviewing the renal safety of metformin. Which statement correctly describes the principal renal safety concern and the consensus continuation threshold for metformin?
A) Metformin causes direct nephrotoxic tubular injury and must be stopped once eGFR falls below 60 mL per minute per 1.73 m squared
B) Metformin precipitates hyperkalemia through aldosterone antagonism and should be stopped below eGFR 45 mL per minute per 1.73 m squared
C) Metformin accumulates in advanced renal impairment and raises the risk of lactic acidosis through impaired lactate clearance; the consensus continuation threshold is eGFR at or above 30 mL per minute per 1.73 m squared, with dose reduction below 45
D) Metformin causes euglycemic diabetic ketoacidosis in CKD and should be stopped below eGFR 30 mL per minute per 1.73 m squared
E) Metformin has no renal clearance dependence and can be continued unchanged at any eGFR
ANSWER: C
Rationale:
Metformin accumulates in advanced renal impairment and raises the risk of lactic acidosis through impaired lactate clearance. The current consensus threshold for metformin continuation is eGFR at or above 30 mL per minute per 1.73 m squared, with dose reduction recommended below 45 mL per minute per 1.73 m squared.
Option A: Option A is incorrect because metformin does not cause direct nephrotoxic tubular injury, and continuation is supported well below an eGFR of 60.
Option B: Option B is incorrect because metformin does not cause hyperkalemia through aldosterone antagonism; that concern relates to RAAS blockade and mineralocorticoid receptor antagonists.
Option D: Option D is incorrect because euglycemic diabetic ketoacidosis is a risk associated with SGLT-2 inhibitors, not metformin.
Option E: Option E is incorrect because metformin clearance is renally dependent and accumulation in CKD is the basis for the eGFR threshold.
7. SGLT-2 inhibitors and renin-angiotensin-aldosterone system (RAAS) blockade both reduce intraglomerular pressure but act at different hemodynamic nodes of the glomerular circuit. Which description correctly pairs each class with its site of action?
A) SGLT-2 inhibitors reduce intraglomerular pressure by constricting the afferent arteriole through tubuloglomerular feedback, while RAAS blockade reduces it by dilating the efferent arteriole
B) SGLT-2 inhibitors dilate the efferent arteriole, while RAAS blockade constricts the afferent arteriole
C) Both classes act by constricting the afferent arteriole, producing redundant rather than additive effects
D) Both classes act by dilating the efferent arteriole, which is why they cannot be combined
E) SGLT-2 inhibitors raise intraglomerular pressure while RAAS blockade lowers it, so the two effects cancel
ANSWER: A
Rationale:
SGLT-2 inhibition reduces intraglomerular pressure by constricting the afferent arteriole through tubuloglomerular feedback, whereas RAAS blockade reduces intraglomerular pressure by dilating the efferent arteriole; because they act at different nodes of the same glomerular pressure circuit, their effects are additive.
Option B: Option B inverts the two mechanisms and is incorrect.
Option C: Option C is incorrect because the two classes act at different arterioles, so their effects are complementary rather than redundant.
Option D: Option D is incorrect because both classes are in fact combined for additive nephroprotection, and the stated shared efferent mechanism is wrong.
Option E: Option E is incorrect because both classes lower intraglomerular pressure rather than opposing one another.
8. The CREDENCE trial enrolled patients with T2DM and diabetic kidney disease (eGFR 30 to 90, urinary albumin-to-creatinine ratio above 300 mg per gram) who were already on maximum tolerated RAAS blockade. What did this trial establish about canagliflozin in this population?
A) Canagliflozin reduced renal events only in patients not yet on RAAS blockade, indicating the two cannot be combined
B) Canagliflozin produced a roughly 30% reduction in the primary renal composite on top of background RAAS blockade, confirming additive nephroprotection from dual-pathway intraglomerular pressure reduction
C) Canagliflozin increased the rate of the renal composite, demonstrating that SGLT-2 inhibitors accelerate kidney decline in established nephropathy
D) Canagliflozin showed benefit only on glycemic endpoints, with no effect on renal outcomes
E) Canagliflozin was effective only in patients with normoalbuminuria and offered no benefit in macroalbuminuric disease
ANSWER: B
Rationale:
CREDENCE demonstrated approximately a 30% reduction in the primary renal composite with canagliflozin on top of background maximum tolerated RAAS blockade, confirming additive nephroprotection from dual-pathway intraglomerular pressure reduction.
Option A: Option A is incorrect because the benefit was demonstrated specifically in patients already on maximal RAAS blockade, proving the effects are additive rather than mutually exclusive.
Option C: Option C is incorrect because canagliflozin reduced, rather than increased, the renal composite.
Option D: Option D is incorrect because the trial established a renal outcome benefit, not merely a glycemic one.
Option E: Option E is incorrect because the enrolled population had macroalbuminuria (UACR above 300 mg per gram), which is precisely where benefit was shown.
9. A patient with T2DM and CKD stage G3b (eGFR 35 mL per minute per 1.73 m squared) is currently taking glibenclamide (glyburide). The pharmacist flags this agent as inappropriate for the degree of renal impairment. What is the pharmacological basis for avoiding this sulfonylurea as eGFR declines?
A) Glibenclamide is converted to an inactive metabolite that paradoxically blocks insulin secretion in CKD
B) Glibenclamide loses all hypoglycemic efficacy in renal impairment, leading to uncontrolled hyperglycemia
C) Glibenclamide causes direct glomerular injury that accelerates progression of diabetic kidney disease
D) Glibenclamide has active, renally cleared metabolites that accumulate in CKD, prolonging the insulin secretory stimulus and substantially raising hypoglycemia risk, so it should generally be avoided below eGFR 45 mL per minute per 1.73 m squared
E) Glibenclamide induces lactic acidosis in renal impairment through the same mechanism as metformin
ANSWER: D
Rationale:
Sulfonylureas with active renally cleared metabolites, particularly glibenclamide (glyburide), accumulate in CKD, prolonging the insulin secretory stimulus and substantially raising hypoglycemia risk; these agents should generally be avoided below eGFR 45 mL per minute per 1.73 m squared.
Option A: Option A is incorrect because the accumulating metabolites are active and enhance, rather than block, the insulin secretory stimulus.
Option B: Option B is incorrect because the agent does not lose efficacy; the problem is excess and prolonged effect causing hypoglycemia.
Option C: Option C is incorrect because the concern is hypoglycemia from metabolite accumulation, not direct glomerular injury.
Option E: Option E is incorrect because lactic acidosis is a metformin-associated risk, not a sulfonylurea mechanism.
10. A patient with T2DM and diabetic kidney disease has persistent albuminuria despite maximally tolerated RAAS blockade and an SGLT-2 inhibitor. The nephrologist proposes adding finerenone. Which statement best characterizes finerenone and its supporting evidence?
A) Finerenone is a steroidal mineralocorticoid receptor antagonist with a higher hyperkalemia rate than spironolactone
B) Finerenone is an SGLT-2 inhibitor that provides redundant afferent arteriolar effects
C) Finerenone is an angiotensin receptor blocker approved as a substitute for RAAS blockade in DKD
D) Finerenone is a potassium-sparing diuretic with no demonstrated effect on renal outcomes
E) Finerenone is a non-steroidal mineralocorticoid receptor antagonist approved for DKD based on FIDELIO-DKD, which showed reductions in renal composite endpoints on background RAAS blockade with a more favorable hyperkalemia profile than steroidal MRAs
ANSWER: E
Rationale:
Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) that received regulatory approval for diabetic kidney disease based on FIDELIO-DKD, which demonstrated significant reductions in renal composite endpoints in T2DM with DKD on background RAAS blockade, with a more favorable hyperkalemia profile than steroidal MRAs such as spironolactone.
Option A: Option A is incorrect because finerenone is non-steroidal and has a more favorable, not worse, hyperkalemia profile than spironolactone.
Option B: Option B is incorrect because finerenone is not an SGLT-2 inhibitor and does not act through afferent arteriolar tubuloglomerular feedback.
Option C: Option C is incorrect because finerenone is not an angiotensin receptor blocker and is added on top of RAAS blockade rather than substituting for it.
Option D: Option D is incorrect because finerenone is an MRA with demonstrated renal outcome benefit, not an inert potassium-sparing diuretic.
11. A patient with T2DM and advanced CKD (eGFR 14 mL per minute per 1.73 m squared) on hemodialysis needs an oral agent that does not require renal dose adjustment. Among dipeptidyl peptidase-4 (DPP-4) inhibitors, which agent is appropriate without dose reduction across the full range of renal function?
A) Sitagliptin, which requires no dose adjustment at any eGFR
B) Alogliptin, which is cleared hepatically and needs no renal adjustment
C) Linagliptin, which does not require dose adjustment for renal impairment and is appropriate even in advanced CKD and dialysis
D) Glibenclamide, because sulfonylureas are renally safe in dialysis patients
E) Canagliflozin, which is the preferred oral agent in dialysis-dependent patients
ANSWER: C
Rationale:
Among DPP-4 inhibitors, linagliptin does not require dose adjustment and is appropriate in advanced CKD and dialysis because it undergoes predominantly biliary/enterohepatic elimination rather than renal clearance; sitagliptin, alogliptin, and saxagliptin all require downward dose adjustment as eGFR falls, making linagliptin a useful oral option when most other agents must be avoided.
Option A: Option A is incorrect because sitagliptin requires dose reduction as eGFR falls.
Option B: Option B is incorrect because alogliptin also requires dose reduction in renal impairment.
Option D: Option D is incorrect because sulfonylureas such as glibenclamide accumulate in renal failure and substantially raise hypoglycemia risk, making them inappropriate in dialysis patients.
Option E: Option E is incorrect because SGLT-2 inhibitors like canagliflozin lose glycemic efficacy at low eGFR and are not the preferred agent in dialysis-dependent patients.
12. A cardiologist notes that one anti-diabetic class has become disease-modifying therapy for heart failure across the entire ejection fraction spectrum, in patients with and without diabetes. Which statement accurately describes this development?
A) SGLT-2 inhibitors reduce the composite of cardiovascular death or heart failure hospitalization in both heart failure with reduced ejection fraction (DAPA-HF, EMPEROR-Reduced) and heart failure with preserved ejection fraction (EMPEROR-Preserved, DELIVER), with benefit independent of diabetes status
B) DPP-4 inhibitors are the only class shown to reduce heart failure hospitalization across the ejection fraction spectrum
C) Thiazolidinediones reduce heart failure events across all ejection fraction categories through PPAR-gamma activation
D) Sulfonylureas have become first-line disease-modifying therapy for heart failure with reduced ejection fraction
E) GLP-1R agonists are the established disease-modifying class for heart failure with preserved ejection fraction
ANSWER: A
Rationale:
SGLT-2 inhibitors are disease-modifying therapy across the full ejection fraction spectrum: in heart failure with reduced ejection fraction, dapagliflozin (DAPA-HF) and empagliflozin (EMPEROR-Reduced) reduced the composite of cardiovascular death or heart failure hospitalization, and in heart failure with preserved ejection fraction, empagliflozin (EMPEROR-Preserved) and dapagliflozin (DELIVER) reduced the heart failure hospitalization composite, with benefit seen regardless of diabetes status.
Option B: Option B is incorrect because DPP-4 inhibitors do not reduce heart failure events and one agent in the class increased them.
Option C: Option C is incorrect because thiazolidinediones worsen heart failure through fluid retention rather than reducing events.
Option D: Option D is incorrect because sulfonylureas have no disease-modifying heart failure role.
Option E: Option E is incorrect because GLP-1R agonists have not consistently demonstrated heart failure-specific benefit and are not established disease-modifying therapy for HFpEF.
13. A patient with T2DM and New York Heart Association (NYHA) class III heart failure is being considered for pioglitazone to improve glycemic control. Why is a thiazolidinedione (TZD) contraindicated in this setting?
A) TZDs cause direct negative inotropy that acutely lowers cardiac output
B) TZDs promote sodium and water retention through peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation in the collecting duct, exacerbating fluid overload and increasing heart failure hospitalization; they are contraindicated in NYHA class III or IV
C) TZDs induce euglycemic diabetic ketoacidosis that decompensates heart failure
D) TZDs cause profound diuresis leading to hypovolemic shock in heart failure patients
Thiazolidinediones promote sodium and water retention through PPAR-gamma activation in the collecting duct, which exacerbates fluid overload and has been associated with increased heart failure hospitalization; for this reason pioglitazone and rosiglitazone are contraindicated in NYHA class III or IV heart failure and used with great caution in class II.
Option A: Option A is incorrect because the mechanism is fluid retention, not direct negative inotropy.
Option C: Option C is incorrect because euglycemic diabetic ketoacidosis is associated with SGLT-2 inhibitors, not TZDs.
Option D: Option D is incorrect because TZDs cause fluid retention rather than diuresis.
Option E: Option E is incorrect because the heart failure risk arises from volume expansion, not accelerated plaque rupture.
14. A patient with T2DM and established heart failure is on a DPP-4 inhibitor. The team is reviewing whether the specific agent is appropriate given the heart failure history. Which DPP-4 inhibitor was associated with increased heart failure hospitalization and should be avoided in patients with established or high-risk heart failure?
A) Linagliptin, which increased heart failure hospitalization in the CARMELINA trial
B) Sitagliptin, which increased heart failure hospitalization in the TECOS trial
C) Metformin, which is a DPP-4 inhibitor associated with heart failure risk
D) Saxagliptin, which was associated with a 27% increase in heart failure hospitalization versus placebo in the SAVOR-TIMI 53 trial, a finding not replicated with other DPP-4 inhibitors
E) Empagliflozin, which is a DPP-4 inhibitor that raises heart failure hospitalization
ANSWER: D
Rationale:
Saxagliptin was associated with a 27% increase in heart failure hospitalization compared with placebo in the SAVOR-TIMI 53 trial, a finding not replicated with other DPP-4 inhibitors; saxagliptin should therefore be avoided in patients with established heart failure or high heart failure risk.
Option A: Option A is incorrect because linagliptin demonstrated neutral heart failure outcomes in CARMELINA.
Option B: Option B is incorrect because sitagliptin demonstrated neutral heart failure outcomes in TECOS.
Option C: Option C is incorrect because metformin is a biguanide, not a DPP-4 inhibitor, and is not associated with heart failure risk.
Option E: Option E is incorrect because empagliflozin is an SGLT-2 inhibitor that reduces, rather than increases, heart failure hospitalization.
15. A patient with T2DM on chronic empagliflozin is admitted for acute decompensated heart failure (ADHF) and is being kept fluid-restricted and intermittently fasting. What is the recommended management of the SGLT-2 inhibitor during this hospitalization?
A) Continue it unchanged because SGLT-2 inhibitors are protective during acute decompensation
B) Increase the dose to enhance natriuresis and accelerate decongestion
C) Hold it during the hospitalization and restart only after clinical stabilization, because of the risks of euglycemic diabetic ketoacidosis and excessive volume depletion in the fasting, fluid-restricted patient
D) Replace it permanently with a thiazolidinedione for ongoing heart failure management
E) Switch it to a sulfonylurea to maintain glycemic control during the acute illness
ANSWER: C
Rationale:
SGLT-2 inhibitors should be held during acute decompensated heart failure hospitalization and restarted only after clinical stabilization, because the fasting, fluid-restricted state raises the risk of euglycemic diabetic ketoacidosis and excessive volume depletion.
Option A: Option A is incorrect because continuation during the acute fasting state is precisely what creates the euglycemic DKA risk.
Option B: Option B is incorrect because increasing the dose would worsen volume depletion in an already fluid-restricted patient.
Option D: Option D is incorrect because thiazolidinediones are contraindicated in advanced heart failure due to fluid retention.
Option E: Option E is incorrect because substituting a sulfonylurea introduces hypoglycemia risk and is not the recommended approach to the held SGLT-2 inhibitor.
16. A pregnant patient with gestational diabetes mellitus (GDM) has fasting and postprandial glucose values that remain above target despite an adequate trial of medical nutrition therapy. According to the regulatory standard of care, which pharmacological agent should be initiated?
A) Insulin, which is the standard of care for diabetes in pregnancy because it is the agent with long-term pregnancy safety data and dose-titratable precision
B) Empagliflozin, because SGLT-2 inhibitors are preferred for their renal safety in pregnancy
C) Semaglutide, because GLP-1R agonists are first-line for glycemic control in pregnancy
D) Glibenclamide, because sulfonylureas are the established first-line oral agent in pregnancy
E) Pioglitazone, because thiazolidinediones are safe across all trimesters
ANSWER: A
Rationale:
Insulin is the pharmacological standard of care for GDM requiring treatment and for all pre-existing diabetes in pregnancy because it is the only agent with long-term pregnancy safety data, offers dose-titratable precision, and is the regulatory standard of care.
Option B: Option B is incorrect because SGLT-2 inhibitors are contraindicated in the second and third trimesters owing to concerns about fetal renal development.
Option C: Option C is incorrect because GLP-1R agonists lack adequate pregnancy safety data and carry fetal safety concerns.
Option D: Option D is incorrect because sulfonylureas are not the established first-line agent and insulin is preferred.
Option E: Option E is incorrect because thiazolidinediones lack pregnancy safety data and are not recommended.
17. A patient with pre-existing T2DM managed on semaglutide and empagliflozin reports that she is planning pregnancy. Which statement correctly describes the pregnancy safety status of these non-insulin agents?
A) Both agents are safe to continue throughout pregnancy with no specific concerns
B) GLP-1R agonists are safe in pregnancy, while only SGLT-2 inhibitors must be discontinued
C) SGLT-2 inhibitors are safe in all trimesters, while only GLP-1R agonists carry fetal risk
D) Both agents can be continued through the first trimester and discontinued only at delivery
E) GLP-1R agonists and SGLT-2 inhibitors are contraindicated or not recommended in pregnancy due to absent or inadequate human safety data; semaglutide should be stopped before planned conception and SGLT-2 inhibitors discontinued when pregnancy is recognized
ANSWER: E
Rationale:
GLP-1R agonists, SGLT-2 inhibitors, DPP-4 inhibitors, and thiazolidinediones are all contraindicated or not recommended in pregnancy due to absent or inadequate human safety data. Semaglutide carries a label warning requiring discontinuation at least two months before planned conception, and SGLT-2 inhibitors are contraindicated in the second and third trimesters with labeling advising discontinuation when pregnancy is recognized.
Option A: Option A is incorrect because neither agent is safe to continue throughout pregnancy.
Option B: Option B is incorrect because GLP-1R agonists are not safe in pregnancy; they carry fetal risk in animal studies.
Option C: Option C is incorrect because SGLT-2 inhibitors are not safe in all trimesters; they raise concerns about fetal renal development.
Option D: Option D is incorrect because these agents should be discontinued before or at recognition of pregnancy, not continued through the first trimester until delivery.
18. A pregnant patient with GDM cannot use insulin due to access barriers and refusal of injections. The team considers metformin. Which statement correctly characterizes metformin use in pregnancy?
A) Metformin does not cross the placenta and achieves negligible fetal concentrations
B) Metformin crosses the placenta and achieves fetal concentrations approximating maternal levels; it is used in pregnancy only when insulin cannot be used and is not a first-line option per ADA and ACOG guidance
C) Metformin is the first-line pharmacological agent for GDM, preferred over insulin in all patients
D) Metformin is absolutely contraindicated in pregnancy because of confirmed structural teratogenicity in humans
E) Metformin is equivalent to insulin and may be used interchangeably with no difference in neonatal outcomes
ANSWER: B
Rationale:
Metformin crosses the placenta and achieves fetal concentrations approximating maternal concentrations; while it has not been associated with structural teratogenicity in human studies, follow-up data raised concerns about large-for-gestational-age neonates and childhood adiposity, so it is used in pregnancy only when insulin cannot be used (patient refusal, access barriers) and is not a first-line option per ADA and ACOG guidance.
Option A: Option A is incorrect because metformin does cross the placenta and reaches substantial fetal concentrations.
Option C: Option C is incorrect because metformin is second-line, not preferred over insulin.
Option D: Option D is incorrect because metformin has not been associated with structural teratogenicity in human observational studies, so it is not absolutely contraindicated.
Option E: Option E is incorrect because metformin and insulin are not interchangeable; neonatal outcome differences have been observed.
19. A patient with pre-existing T2DM managed with insulin throughout pregnancy has just delivered. The team anticipates a change in her insulin requirements in the immediate postpartum period. What change should be expected and acted upon?
A) Insulin requirements rise sharply after delivery, requiring an immediate dose increase
B) Insulin requirements remain unchanged from the third-trimester dose for several weeks
C) Insulin requirements rise gradually over the first month, requiring slow uptitration
D) Insulin requirements fall sharply within hours of placental delivery, requiring immediate dose reduction to avoid postpartum hypoglycemia
E) Insulin must be stopped entirely and replaced with an SGLT-2 inhibitor immediately after delivery
ANSWER: D
Rationale:
Insulin requirements fall sharply within hours of placental delivery because the placental hormones that drove second- and third-trimester insulin resistance are withdrawn; immediate insulin dose reduction is therefore required to avoid postpartum hypoglycemia.
Option A: Option A is incorrect because requirements fall, not rise, after delivery.
Option B: Option B is incorrect because the requirement changes abruptly rather than remaining stable.
Option C: Option C is incorrect because the fall is rapid (within hours), not a gradual month-long decline.
Option E: Option E is incorrect because insulin remains the appropriate agent and SGLT-2 inhibitors are not substituted immediately postpartum, particularly with breastfeeding considerations.
20. An 82-year-old man with T2DM has multiple comorbidities, moderate cognitive impairment, and limited life expectancy. His current regimen targets an HbA1c below 6.5%. What is the appropriate glycemic philosophy and target for this patient?
A) Intensify therapy to achieve an HbA1c below 6.0% to maximize long-term microvascular protection
B) Maintain the sub-6.5% target because tighter control always improves outcomes regardless of age
C) Relax the target because hypoglycemia avoidance and functional independence take precedence; a less stringent HbA1c of approximately 7.5 to 8.5% is appropriate given comorbidity and frailty burden
D) Discontinue all glucose-lowering therapy entirely irrespective of symptoms
E) Switch to high-dose insulin to achieve rapid normalization of glucose
ANSWER: C
Rationale:
In older adults with multiple comorbidities, cognitive impairment, frailty, or limited life expectancy, the prevention of hypoglycemia and maintenance of functional independence take precedence over tight glycemic control; the ADA Standards of Care stratify targets by functional status, with a less stringent HbA1c of roughly 7.5 to 8.5% appropriate in this group.
Option A: Option A is incorrect because intensifying to below 6.0% increases hypoglycemia risk with little benefit over this patient's remaining lifespan.
Option B: Option B is incorrect because tighter control does not always improve outcomes and raises hypoglycemia harm in frail elderly patients.
Option D: Option D is incorrect because the goal is relaxation of targets and avoidance of hyperglycemic symptoms, not complete cessation of all therapy.
Option E: Option E is incorrect because high-dose insulin would increase hypoglycemia risk, which is precisely what should be avoided.
21. A 78-year-old woman with T2DM is taking glibenclamide (glyburide). A pharmacist performing a medication review flags this agent against a specific geriatric prescribing guideline. Which statement correctly identifies the guideline concern?
A) The American Geriatrics Society Beers Criteria identifies glibenclamide as a potentially inappropriate medication in adults over 65 because of its prolonged duration of action and risk of severe hypoglycemia
B) The Beers Criteria recommends glibenclamide as the preferred sulfonylurea in adults over 65 due to its short half-life
C) Glibenclamide is flagged only because of its cost, not for any safety reason
D) Glibenclamide is preferred in the elderly because it lacks active metabolites
E) The Beers Criteria flags metformin, not glibenclamide, as inappropriate in older adults
ANSWER: A
Rationale:
The American Geriatrics Society Beers Criteria specifically identifies glibenclamide as a potentially inappropriate medication in adults over 65, owing to its prolonged duration of action and the consequent risk of severe hypoglycemia.
Option B: Option B is incorrect because glibenclamide is long-acting and is flagged against use, not recommended, in older adults.
Option C: Option C is incorrect because the concern is severe hypoglycemia risk, not cost.
Option D: Option D is incorrect because glibenclamide has active renally cleared metabolites that accumulate and prolong its effect.
Option E: Option E is incorrect because metformin is generally acceptable in older adults with preserved renal function; it is glibenclamide that the Beers Criteria flags.
22. An 80-year-old patient with T2DM on a sulfonylurea is started on a new medication and subsequently develops severe hypoglycemia. Polypharmacy and drug interactions are common precipitants of hypoglycemia in elderly diabetic patients. Which of the following co-prescribed drug classes is a recognized precipitant of severe sulfonylurea-associated hypoglycemia?
A) Inhaled corticosteroids, which displace sulfonylureas from skeletal muscle receptors
B) Proton pump inhibitors, which double the renal clearance of sulfonylureas
C) Calcium channel blockers, which directly stimulate pancreatic insulin release
D) Loop diuretics, which enhance sulfonylurea metabolism and raise glucose
E) Azole antifungals, fluoroquinolones, trimethoprim, or fibrates, which can interact with sulfonylureas to precipitate severe hypoglycemia
ANSWER: E
Rationale:
Drug-drug interactions, particularly between sulfonylureas and azole antifungals, fluoroquinolones, trimethoprim, or fibrates, can precipitate severe hypoglycemia in elderly diabetic patients, which is why medication reconciliation at every encounter is essential.
Option A: Option A is incorrect because inhaled corticosteroids tend to raise glucose and do not displace sulfonylureas from muscle receptors.
Option B: Option B is incorrect because proton pump inhibitors do not double sulfonylurea renal clearance.
Option C: Option C is incorrect because calcium channel blockers do not directly stimulate insulin release and are not a recognized cause of sulfonylurea hypoglycemia.
Option D: Option D is incorrect because loop diuretics tend to raise glucose rather than enhance sulfonylurea metabolism, and are not a recognized hypoglycemia precipitant in this context.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.